<DOC>
	<DOCNO>NCT01747382</DOCNO>
	<brief_summary>Recent clinical study demonstrate catheter-based renal sympathetic nerve ablation safe effective treating patient resistant hypertension . However , limited data safety efficacy patient Chronic Kidney Disease . The investigator hypothesize catheter-based renal sympathetic nerve ablation safe effective treatment resistant hypertension patient Chronic Kidney Disease .</brief_summary>
	<brief_title>Renal Denervation Treatment Resistant Hypertension Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Individual systolic blood pressure ≥ 160 mmHg ( ≥ 150 mmHg type 2 diabetic ) . 2 . Individual adhere stable drug regimen include 3 antihypertensive medication , one diuretic , ( change minimum 2 week prior enrollment ) expect maintain least 6 month . 3 . Individual stage 3 chronic kidney disease , define eGFR 30 60 mL/min/1.73m2 , use MDRD calculation . 4 . Individual ≥ 21 ≤ 65 year age . 5 . Individual agrees study procedure perform , competent willing provide write , inform consent participate clinical study 1 . Individual renal artery anatomy ineligible treatment include : 1 . Main renal artery &lt; 4 mm diameter &lt; 20 mm length . 2 . Hemodynamically anatomically significant renal artery abnormality stenosis either renal artery , eye operator , would interfere safe cannulation renal artery meet local standard surgical repair interventional dilation . 3 . A history prior renal artery intervention include balloon angioplasty stenting . 4 . Multiple main renal artery either kidney . 2 . Individual estimate glomerular filtration rate ( eGFR ) &lt; 30mL/min/1.73m2 , use MDRD calculation . 3 . Individual type 1 diabetes mellitus . 4 . Individual experience myocardial infarction , cerebrovascular accident within 6 month screen visit , widespread atherosclerosis , document intravascular thrombosis unstable plaque . 5 . Individual schedule plan surgery cardiovascular intervention next 6 month . 6 . Individual hemodynamically significant valvular heart disease reduction blood pressure would consider hazardous . 7 . Individual implantable cardioverter defibrillator ( ICD ) pacemaker , metallic implant compatible magnetic resonance imaging ( MRI ) . 8 . Individual serious medical condition , opinion investigator , may adversely affect safety and/or effectiveness participant study ( i.e. , patient clinically significant peripheral vascular disease , abdominal aortic aneurysm , bleed disorder thrombocytopenia , hemophilia , significant anemia , arrhythmias atrial fibrillation ) . 9 . Individual pregnant , nurse planning pregnant . [ Female participant childbearing potential must negative serum urine human chorionic gonadotropin ( hCG ) pregnancy test prior treatment . ] 10 . Individual currently enrol another investigational drug device trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Treatment-resistant Hypertension</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Symplicity catheter</keyword>
	<keyword>Renal denervation</keyword>
</DOC>